A Phase I Double Blind, Placebo-Controlled, Randomized Study of the Safety and Immunogenicity of Electroporated HIV DNA with or without Interleukin 12 in Prime-Boost Combinations with an Ad35 HIV Vaccine in Healthy HIV-Seronegative African Adults.

PLoS One · 2015 · PMC4529153 · PMID 26252526

Europe PMC DOI

hedged sentences

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

Although there were some trends to indicate a negative effect of IL-12 on immune responses, the differences did not reach statistical significance.

also in 111,027 other papers

showed a trendno p-value reported

The response rate to any peptide pool (any HIVMAG or GRIN/Env peptide pool) in Group 1 HIVMAG (x3) followed by Ad35-GRIN/Env after all vaccinations showed a trend to higher response rate (73%) than those seen in Groups 4 and 5 (50 and 45% respectively).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.